NEW YORK: The drug giant is paying a 120 pct premium for Medivation. It's a good fit and the biotech's cancer blockbuster is a rare gem.
The whopping premium suggests Pfizer sees something others missed.
But a heated auction and back-of-the-envelope math hint that the buyer is overpaying.
Comments
Comments are closed.